Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | AXL | P30530 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.64 |
| ▸ | NCF1 | P14598 | 5/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 5/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900276 | 0.84 | NCF1 (0.68) | ADRB2HTR6NCF1ADRB1HTR3A | |
| SCHEMBL2244546 | 0.78 | ADRB2 (1.00) | ADRB2ADRA2AHTR2CAXLHRH1 | |
| SCHEMBL2214176 | 0.75 | HTR6 (0.49) | ADRB2ADRA2AHTR2CAXLHRH1 | |
| SCHEMBL5369315 | 0.73 | NCF1 (0.53) | ADRB2HTR6NCF1ADRB1HTR3A | |
| SCHEMBL8237908 | 0.72 | NCF1 (0.72) | ADRB2ADRA2AHTR2CAXLHRH1 | |
| SCHEMBL900166 | 0.72 | ADRB1 (0.62) | ADRB2NCF1ADRB1HTR3AHTR1A | |
| SCHEMBL12215522 | 0.72 | KMT2A (0.49) | — | |
| SCHEMBL6709128 | 0.71 | HTR3A (0.63) | HTR6NCF1ADRB1HTR3AHTR1A | |
| SCHEMBL31652018 | 0.71 | HTR3A (0.69) | HTR6ADRB1HTR3AHTR1AHTR3E | |
| SCHEMBL3973132 | 0.71 | HTR3A (0.69) | HTR6ADRB1HTR3AHTR1AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039486-B2 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1638568-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1638568-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| EP-1638568-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050261296-A1 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| WO-2005004801-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | IDO2, IDO1, INMT | ADRB2 1035/4885ADRA2A 1329/4885HTR2C 287/4885 |
| US-20050261296-A1 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | MALT1, BCL6, CD4 | ADRB2 4284/4885ADRA2A 4288/4885HTR2C 3776/4885 |
| US-20080132516-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | IDO2, IDO1, INMT | ADRB2 1620/4885ADRA2A 2293/4885HTR2C 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.